Tuesday February 17, 2026
For those of you in the US, we hope you had a nice President’s Day weekend.
If there’s a theme emerging this week, it’s strategic positioning — large-cap portfolio moves, AI infrastructure bets, and distribution partnerships all reinforcing that commercialization discipline is separating momentum from noise.
8 things to watch this week:
1. 💰 Danaher closes nearly $10B deal for Masimo’s consumer unit
Danaher has closed its nearly $10B acquisition of Masimo’s consumer business, continuing its portfolio refinement strategy. For device leaders, the signal is clear: strategic buyers remain active, but capital is flowing toward focused, thesis-driven assets.
Reuters
2. 🧠 Before You Execute, Pressure-Test the Commercial Story
Most medtech missteps don’t come from bad execution.
They come from acting on assumptions that were never examined.
The CLIF Analysis is a fast, external review of how your company presents itself—based on your pitch deck, website, and public materials. We assess where the story is clear, where it relies on assumptions, and where gaps may create downstream risk.
Not a roadmap. Not execution.
A structured reality check to help leaders decide whether deeper readiness work is warranted.
3. 🤖 GE HealthCare and BARDA launch $35M AI ultrasound collaboration
GE HealthCare is partnering with BARDA on a $35M AI-enabled ultrasound initiative to strengthen diagnostic readiness. Public-private AI infrastructure investments continue to expand, signaling durable federal support for embedded clinical AI.
MassDevice
4. 📈 Medtronic earnings: Can new products fuel growth?
Medtronic’s latest earnings raise a familiar question: can pipeline innovation reaccelerate growth? For established device companies, operational stability is no longer enough — product velocity and category expansion remain central to valuation.
Investing.com
5. 🤝 How CathWorks leaned on its partner Medtronic to succeed
CathWorks credits its partnership with Medtronic as a key lever in scaling adoption. Strategic channel alignment continues to be one of the clearest paths from regulatory clearance to meaningful market penetration.
Medical Design & Outsourcing
6. 💵 Nanochon targets $20M Series A after strong start to 2026
Nanochon is pursuing a $20M Series A following early traction in orthopedics. Venture capital in med device remains selective, with investors favoring companies that combine technical differentiation with credible commercialization strategy.
VoxelMatters
7. 🏠 Owlet partners with PromptCare to expand BabySat pulse oximeter footprint
Owlet has partnered with PromptCare to broaden distribution of its BabySat pulse oximeter. As care continues shifting beyond hospital walls, HME channel strategy is becoming increasingly central to remote monitoring growth.
HME News
8. 🌍 Median Technologies establishes distribution partnership
Median Technologies announced a new distribution partnership to expand its commercial reach. For software-enabled medtech companies, distribution infrastructure often determines how quickly regulatory wins translate into revenue.
Yahoo Finance
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.